__NUXT_JSONP__("/drugs/Narnatumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"1188275-92-4",chebiId:b,chemicalFormula:b,definition:"A fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor), with potential antineoplastic activity. Anti-RON monoclonal antibody IMC-RON8 binds to RON, thereby preventing binding of its ligand hepatocyte growth factor-like protein (HGFL or macrophage-stimulating protein (MSP)). This may prevent RON receptor-mediated signaling and may prevent cellular proliferation in tumor cells overexpressing RON. RON, a receptor tyrosine kinase, is overexpressed in a variety of epithelial cancer cell types and plays an important role in cellular proliferation, migration and invasion.",fdaUniiCode:"R42YK40U9M",identifier:"C91382",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["Anti-RON Monoclonal Antibody IMC-RON8","IMC-RON8","NARNATUMAB",a]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNarnatumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Narnatumab","","2021-10-30T13:47:22.613Z")));